DrugsControl Media Services

News Detail

Adjuvant Osimertinib can cut risk of death from lung cancer by half (05-06-2023)

Chicago, 5 June 2023: Adjuvant osimertinib can improve overall survival (OS) in patients with EGFR-mutated, early-stage non-small-cell lung cancer (NSCLC), according to results from the ADAURA trial presented at the ASCO Annual Meeting 2023.1

View Details
Source : Cancer Therapy Advisor
lung cancer Researchers death risk study Science News ASCO 2023 non-small cell lung cancer

Related News